Senores Pharmaceuticals peers

Companies like Senores Pharmaceuticalslatest year

Market cap and P/E at the last close; sales growth is the latest quarter on the same quarter a year before; ROE for the latest financial year.

Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

SENORES₹1,324.30

Senores Pharmaceuticals Limited

· Pharma & Health
₹ CrorePeersSANOFIINNOVACAPMOREPENLABIOLCPFDCPGHLSANOFICONRORCHPHARMAMcap ₹6,098 Cr
Comp Set
In ₹ Crore except Per Share
Latest Annual
SENORES
FY26
SANOFI
FY25
INNOVACAP
FY26
MOREPENLAB
FY26
Peer
Average
Valuation — at last close
P/E50.18×◆ 16.67×41.95×72.59×43.74× +15%
P/B6.53×8.00×5.55×◆ 5.52×6.36× +3%
EV/EBITDA37.41×◆ 13.42×25.96×55.60×31.66× +18%
Market Cap₹6,098 Cr₹6,882 Cr₹6,007 Cr₹6,881 Cr₹6,590 Cr -7%
Growth
Revenue CAGR 3Y———8.40%8.40%
Revenue CAGR 5Y———8.73%8.73%
Net Income CAGR 3Y———34.87%34.87%
Revenue YoY (latest Q)18.90%-25.80%33.94%◆ 81.38%29.84% -37%
Net Income YoY (latest Q)21.51%-33.70%42.27%◆ 117.48%42.02% -49%
Profitability
EBITDA Margin◆ 26.61%24.38%14.90%6.96%15.41% +73%
Net Income Margin19.21%◆ 20.53%8.78%5.25%11.52% +67%
Return on Common Equity14.13%◆ 44.07%14.03%7.90%22.00% -36%
Return on Capital Employed12.66%◆ 46.43%15.38%6.55%22.79% -44%
Return on Assets8.59%◆ 24.85%8.38%5.11%12.78% -33%
Credit & Quality
Total Debt/Equity0.34×◆ 0.00×0.32×0.16×0.16× +113%
Interest Coverage5.48×◆ 302.73×11.70×5.43×106.62× -95%
Scale — latest FY
Revenue / Total Income₹633 Cr₹2,013 Cr₹1,630 Cr₹1,806 Cr₹1,816 Cr -65%
Net Income₹122 Cr₹413 Cr₹143 Cr₹94.9 Cr₹217 Cr -44%
Total Assets₹1,604 Cr₹1,612 Cr₹1,838 Cr₹1,936 Cr₹1,795 Cr -11%
EPS₹26.39₹179.46₹25.02₹1.73₹68.74 -62%
Book Value per Share₹202.74₹374.17₹188.99₹22.75₹195.3 +4%
◆ best value in the comp set per metric · Δ = subject vs average of the other companies.
« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.